Frederic Kinkead
Montreal, QC H3B0G7, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Comparison of deep prostate-specific antigen response in Black patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide.
Journal: Journal of comparative effectiveness research
Published: January 16, 2026
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States.
Journal: ClinicoEconomics and outcomes research : CEOR
Published: January 07, 2026
Comparison of Prostate-Specific Antigen Response in Black Patients with Metastatic Castration-Sensitive Prostate Cancer Initiated on Apalutamide vs Abiraterone Acetate.
Journal: Journal of health economics and outcomes research
Published: October 02, 2025
Response to Letter to the Editor Regarding: 'Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer'.
Journal: Advances in therapy
Published: August 15, 2025
Real-world comparative effectiveness of apalutamide versus enzalutamide for prostate-specific antigen response in metastatic castration-sensitive prostate cancer.
Journal: Therapeutic advances in medical oncology
Published: August 12, 2025
Healthcare resource utilization and costs among patients with metastatic castration-sensitive prostate cancer initiated on apalutamide or enzalutamide in the United States (2019-2023).
Journal: Journal of medical economics
Published: July 15, 2025
Overall survival in patients with metastatic castration-sensitive prostate cancer treated with apalutamide versus abiraterone acetate: a head-to-head analysis of real-world patients in the USA.
Journal: Journal of comparative effectiveness research
Published: May 09, 2025
Healthcare Costs Associated with Adverse Events in Pediatric Patients with Attention-Deficit/Hyperactivity Disorder (ADHD): A Claims-Based Study.
Journal: Advances in therapy
Published: May 08, 2025
Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US.
Journal: Future oncology (London, England)
Published: April 07, 2025
Corrigendum to 'Attainment of early, deep prostate-specific antigen response in metastatic castration-sensitive prostate cancer: A comparison of patients initiated on apalutamide or enzalutamide'[Urol Oncol: Semin Original Investigat 41(3) (2023) 253.e1-253.e9].
Journal: Urologic oncology
Published: March 28, 2025
Overall Survival with Apalutamide Versus Enzalutamide in Metastatic Castration-Sensitive Prostate Cancer.
Journal: Advances in therapy
Published: March 03, 2025
Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States.
Journal: Journal of managed care & specialty pharmacy
Published: July 01, 2024
Last Updated: 09/26/2026